ZILRETTA decreased peak systemic exposure
18x lower peak plasma concentration with ZILRETTA
Reduced peak systemic exposure to triamcinolone acetonide (TA) (1144 pg/mL) compared to TAcs (21,062 pg/mL)a
- Results based on a study evaluating concentration of TA in plasma following a single intra-articular injection of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) (n=60) or TAcs (n=18)2
- ZILRETTA: blood samples were collected periodically over 24 hours and at Weeks 1, 6, 12, 16, or 20
- TAcs: samples were collected periodically over 24 hours and at Week 6
- Based on Cmax levels following a single intra-articular injection of ZILRETTA.
TAcs=triamcinolone acetonide crystalline suspension.
ZILRETTA injection demonstrated minimal effect on blood glucose
In a study evaluating a single dose of ZILRETTA in patients with type 2 diabetes (n=18), glucose values were 155.2 mg/dL at baseline (average over 72 hours prior to injection) and 163.4 mg/dL post injection (average over 72 hours post dosing)3
The clinical relevance of plasma exposure and blood glucose information is unknown